We are scientists and doctors. We engage in a large number of scientific projects and international collaborations that contribute to the advancement of knowledge in the diagnosis and prognosis of leukemias and lymphomas. Moreover, we promptly develop and implement the latest technical innovations, including test procedures, devices and individual tests. In doing so, we are significant drivers of progress in laboratory diagnostics and routines.
Innovation - shaping the future
Implementation on the cutting edge
Steady innovation, the implementation of the latest scientific insight, devices and methods – as well as their scalability – are key to rapid advancement in diagnostics. Our clear scientific focus and a broad range of international collaborations help us drive this outstanding innovation at the necessary speed and in the required quality.
Automation - Making processes reproducible
Modern diagnostics are predicated on standard operating procedures (SOP) – reproducible and automated process steps – and state-of-the-art technologies, as well as thoroughly trained and highly educated employees. MLL has automated and standardized its workflows to the greatest possible extent, and devices are controlled by a central software platform. Samples are always fitted with barcodes for processing. Controlling laboratory processes and ensuring the integration of external software solutions, our proprietary laboratory information and management system (LIMS) optimizes all of our procedures.
Exploiting digitization effectively
Our team and the equipment it uses work with comprehensive software solutions and maximum automation, supported wherever purposeful by artificial intelligence to ensure precisely the right outcome to match your individual requirements. Here, we draw on fully automatic, software-driven and barcode-controlled processing and treatment of blood and bone marrow samples by state-of-the-art robots and measurement systems. Controlled by a central software structure, the findings are shared directly between the devices and staff during operation and sample analysis.
Diagnostics of the future
Today, we are engaged with the topics of new methodological developments, automation, the Internet of Things (IoT), big data, cloud computing, data security, and artificial intelligence. These aspects have not stood still even in the field of medicine – on the contrary, they allow us to forge new paths and to further improve diagnostics for our patients. What motivates us is putting these new technologies to the test and gradually making them available to each of our patients in routine diagnostics.
5,000 genome project
From phenotype to genotype. We set a goal to sequence 5,000 genomes and transcriptomes from as many different leukemia and lymphoma entities as possible in one year. We have learned in this year to sequence genomes and transcriptomes at the highest quality level, with high throughput, in the shortest possible time in a clinical setting. We are now applying this experience and expertise to analyze the data in new ways and use artificial intelligence to reproduce common diagnostics and develop a genetic classification of leukemias and lymphomas.
Besides routine diagnostics with rapid turn-around times, MLL focuses on applied research for leukemia diagnostics. We believe that our central task is to encourage discussion of our knowledge, data and findings and to place them at the disposal of the scientific community in talks, training and publications. We have contributed to a broad variety of collaborations on scientific issues within hematology for more than 20 years, especially through our international networks with other diagnostic laboratories and research groups around the world.
Each year, we receive more than 75,000 samples, which are examined by our routine diagnostics. Upon receipt of the sample, a decision is made based on the submitting physician’s requirements as to which methods (cytomorphology, cytogenetics/FISH, immumophenotyping, molecular genetics) the sample is to be subjected to for diagnostics. Furthermore, particularly in the case of molecular genetic analyses, the submitting party also has the option of having material preserved so that specific analyses can be ordered as needed at a later point in time. For 40% percent of submissions, the patient also submits a declaration of consent permitting us to preserve the material and utilize it for research purposes in the future where necessary. Hence, since MLL’s inception, we have been able to build a comprehensive biobank, which currently makes it possible to address a large number of questions in a targeted fashion.
Global collaboration - We research and publish hand-in-hand with our national and international cooperation
partners from science and business; discoveries and insights are made
public in journals, talks, press releases or technical notes.
We enter into collaborations with renowned researchers who are world leaders in their scientific field. By combining their expertise and research activities with the knowledge we have gained and deepening it through joint scientific activities, we are expanding our understanding of leukemias and lymphomas. But innovation and technical advancement is also not possible without industrial partners with whom we jointly advance diagnostics.
The diagnostic concepts emerging in our company collaborations aim to continuously improve the quality of test results, develop new diagnostic parameters and establish valid procedures with improved efficiency of laboratory processes. The industrial cooperation partners include: